This group focuses on maintaining the supply of critical medical technologies. Policies and other actions which seek to limit exposure to Ethylene Oxide (EtO) for medical device sterilization and use restrictions governing per and poly-fluoroalkyl substances (PFAS) should be balanced to ensure the global supply of critical medical technologies is not impeded. MDMA works collaboratively with member companies to engage local, state, federal, and international governments, key agencies, and other stakeholders to limit supply chain disruptions and advocate for risk-based regulatory solutions.